Eqis Capital Management, Inc. Enanta Pharmaceuticals Inc Transaction History

Eqis Capital Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 05, 2019	SELL	$60.08 - $88.17 $154,585 - $226,861	-2,573 Closed	0 $0
Q2 2019 Jul 18, 2019	SELL	$81.3 - $97.35 $259,021 - $310,157	-3,186 Reduced 55.32%	2,573 $217,000
Q1 2019 Apr 18, 2019	BUY	$69.08 - $105.66 $82,688 - $126,475	1,197 Added 26.24%	5,759 $550,000
Q4 2018 Jan 25, 2019	BUY	$65.41 - $84.65 $34,863 - $45,118	533 Added 13.23%	4,562 $323,000
Q3 2018 Oct 17, 2018	SELL	$85.46 - $126.37 $37,687 - $55,729	-441 Reduced 9.87%	4,029 $366,000
Q2 2018 Jul 27, 2018	SELL	$81.85 - $120.51 $2.22 Million - $3.27 Million	-27,157 Reduced 85.87%	4,470 $518,000
Q1 2018 Apr 06, 2018	BUY	$57.91 - $92.15 $30,576 - $48,655	528 Added 1.7%	31,627 $2.56 Million
Q4 2017 Jan 25, 2018	BUY	$45.65 - $59.37 $45,513 - $59,191	997 Added 3.31%	31,099 $1.83 Million
Q3 2017 Oct 03, 2017	BUY	$37.91 - $46.8 $1.14 Million - $1.41 Million	30,102	30,102 $1.41 Million

108

19.7M

9.7K

12.4K

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $133M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Eqis Capital Management, Inc. with notifications on news.